Mendelian Randomization Study Evidence On The Association Between Herpes Simplex Virus Antibodies Immune Response And The Risk Of Drug-Induced Obesity

Xiaoping Li, Weikun Zhao, Yun Li, Hong ChenClinical 2025 · DOI

Abstract

This study utilized Mendelian randomization (MR) to investigate the causal link between immune response to herpes simplex virus antibodies and drug-induced obesity (DIO). Genome-wide association study (GWAS) data was analyzed using methods like Inverse Variance Weighted (IVW), MR-Egger, and Weighted Median method (WME). Effective instrumental variables were identified, showing a significant increase in DIO risk with Epstein-Barr virus ZEBRA antibody, herpes simplex virus 7 U14 antibody, herpes simplex virus type 1 IgG, and herpes simplex virus type 2 IgG seropositivity. Reverse MR analysis did not reveal a reverse causal relationship. The study provides initial evidence of the relationship between herpes simplex virus antibody immune response and DIO, contributing new theoretical insights for future understanding of DIO.

Introduction

Drug-Induced Obesity (DIO) represents a significant clinical hurdle, frequently resulting from the long-term administration of essential medications such as glucocorticoids and antipsychotics. While the metabolic side effects of these drugs—including weight gain and insulin resistance—are well-documented, the degree of susceptibility varies significantly among patients.

Previous observational research has suggested a potential link between herpesvirus infections and metabolic disorders. However, these studies often struggle with confounding bias, making it difficult to distinguish whether the virus causes obesity, obesity increases viral susceptibility, or external factors like socioeconomic status influence both. This study addresses these challenges by employing a Mendelian Randomization (MR) approach to determine if the immune response to these viruses causally drives the risk of DIO.

Methodology

The researchers utilized a Two-Sample Mendelian Randomization (MR) framework. MR leverages genetic variants, specifically Single Nucleotide Polymorphisms (SNPs), as instrumental variables to represent an exposure—in this case, the immune response to various herpesviruses. Because these genetic variants are randomly allocated at birth, they are inherently shielded from the typical confounding factors found in observational lifestyle studies.

Conceptual framework of the Mendelian Randomization (MR) study design.

The study design incorporated several rigorous statistical checks:

  • Bidirectional Analysis: To rule out reverse causality, the researchers tested whether DIO genetically predisposes individuals to higher viral antibody titers.
  • Robust Statistical Methods: The primary analysis used the Inverse Variance Weighted (IVW) method, supplemented by MR-Egger (to detect horizontal pleiotropy) and Weighted Median methods to ensure consistency across different modeling assumptions.
  • Data Sources: Exposure data for Human Herpesvirus (HHV) antibodies were sourced from a UK Biobank sub-cohort of 8,735 participants. Outcome data for DIO were obtained from the FinnGen R11 repository, which includes data from over 426,000 Finnish participants.

Results and Discussion

The study identified a significant causal relationship between the immune response to several herpesviruses and an increased risk of developing DIO. Specifically, genetically predicted increases in antibody levels for EBV ZEBRA, HHV-7 U14, and IgG seropositivity for HSV-1 and HSV-2 were all associated with higher odds of DIO.

Mendelian Randomization results for the causal effect of EBV ZEBRA antibody on drug-induced obesity (DIO).

Key findings include:

  • EBV ZEBRA: Showed an Odds Ratio (OR) of 1.27 (95% CI: 1.04–1.55, p=0.017).
  • HHV-7 U14: Demonstrated the strongest association with an OR of 1.73 (95% CI: 1.12–2.67, p=0.014).
  • HSV-1 and HSV-2 IgG: Both showed significant increases in risk, with ORs of 1.33 and 1.30 respectively.

These results support the "Latent Trigger" hypothesis, suggesting that latent viral infections may act as silent metabolic disruptors. For instance, viral proteins like HHV-7's U14 can activate the NF-κB signaling pathway, potentially inducing chronic low-grade inflammation that interferes with lipid and glucose metabolism. Importantly, the reverse MR analysis found no evidence that DIO causally affects the viral immune response, strengthening the case for a unidirectional causal path from viral response to obesity risk.

Conclusion

This research provides the first genetic evidence of a causal link between common herpesvirus immune responses and drug-induced obesity. By identifying specific viral markers associated with increased metabolic risk, the study offers a new "multi-hit" perspective on obesity, where latent infections prime the body for dysregulation when triggered by certain medications.

While the findings are robust, limitations include a primary focus on individuals of European ancestry and the need for further exploration of the precise biological mechanisms involved. Future research should aim to validate these results in diverse populations and investigate how specific drug classes interact with viral latency to influence patient outcomes. This work lays the theoretical groundwork for future personalized medicine strategies that could use viral antibody profiling to predict and mitigate DIO risk.

Summary updated

Abstract

This study utilized Mendelian randomization (MR) to investigate the causal link between immune response to herpes simplex virus antibodies and drug-induced obesity (DIO). Genome-wide association study (GWAS) data was analyzed using methods like Inverse Variance Weighted (IVW), MR-Egger, and Weighted Median method (WME). Effective instrumental variables were identified, showing a significant increase in DIO risk with Epstein-Barr virus ZEBRA antibody, herpes simplex virus 7 U14 antibody, herpes simplex virus type 1 IgG, and herpes simplex virus type 2 IgG seropositivity. Reverse MR analysis did not reveal a reverse causal relationship. The study provides initial evidence of the relationship between herpes simplex virus antibody immune response and DIO, contributing new theoretical insights for future understanding of DIO.
BibTeX
@inproceedings{li2025mendelian,
  author = {Xiaoping Li and Weikun Zhao and Yun Li and Hong Chen},
  title = {{Mendelian Randomization Study Evidence On The Association Between Herpes Simplex Virus Antibodies Immune Response And The Risk Of Drug-Induced Obesity}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.70731/thgpbr97},
}
Figure